Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Colchicine may reduce cardiovascular risk in CAD and diabetes patients

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 12, 2026

Key finding

The HR for the treatment effect on the primary endpoint was 0.64 (0.51–0.80) in participants without diabetes.

This study evaluated the effects of colchicine on cardiovascular risk in patients with chronic coronary artery disease and diabetes, finding mixed outcomes based on diabetes status.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Low Risk

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study evaluated the effects of colchicine on cardiovascular risk in patients with chronic coronary artery disease and diabetes, finding mixed outcomes based on diabetes status.

Clinical relevance

These findings are significant as they suggest that colchicine could be a beneficial treatment for reducing cardiovascular risks in patients with chronic coronary artery disease, especially for those without diabetes. This could lead to improved management strategies for cardiovascular health in this population, potentially reducing the burden of cardiovascular events.

Keep in mind

The effectiveness of colchicine in participants with T2DM was unclear. The study's findings may not be generalizable to all populations with diabetes. Sample size and demographic diversity may limit the robustness of the results.

Published in

Journal Reference

Publication details and source links for this paper.

Niekbachsh M, Jan L, Tjerk SJO, et al. Colchicine Reduces Cardiovascular Risk in Patients with Chronic Coronary Artery Disease and Diabetes. Frontiers in Cardiovascular Medicine. 2023;10:1244529. doi:10.3389/fcvm.2023.1244529

View DOIView on PubMedView on PMC

Main Effects

Colchicine reduced cardiovascular death in participants without diabetes (HR 0.64, p = 0.01).

Colchicine did not significantly reduce spontaneous myocardial infarction in participants with T2DM (HR 1.52).

Colchicine showed a decrease in ischemic stroke for participants without diabetes (HR 0.64).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Colchicine 0.5 mg once daily and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Coronary revascularization, Gestational diabetes mellitus incidence, and 2 more.

This study contributes evidence to

Intervention

Colchicine 0.5 mg once daily

Outcome

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topic

Cardiovascular Risk

Primary intervention

Colchicine 0.5 mg once daily

Primary outcomes

  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
  • Coronary revascularization
  • Gestational diabetes mellitus incidence

Evidence topics

Cardiovascular Risk

Primary intervention

Colchicine 0.5 mg once daily

Primary outcomes

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)Coronary revascularizationGestational diabetes mellitus incidence

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 59

1

Related topics

5

Evidence pairs

39

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence topic

Cardiovascular Risk

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Colchicine 0.5 mg once daily → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Colchicine 0.5 mg once daily → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Coronary revascularization

Colchicine 0.5 mg once daily → Coronary revascularization

Colchicine 0.5 mg once daily → Coronary revascularization

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Gestational diabetes mellitus incidence

Colchicine 0.5 mg once daily → Gestational diabetes mellitus incidence

Colchicine 0.5 mg once daily → Gestational diabetes mellitus incidence

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Incidence of myocardial infarction

Colchicine 0.5 mg once daily → Incidence of myocardial infarction

Colchicine 0.5 mg once daily → Incidence of myocardial infarction

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Ischemic stroke

Colchicine 0.5 mg once daily → Ischemic stroke

Colchicine 0.5 mg once daily → Ischemic stroke

Evidence Intelligence™
ImpactScore™
25
Negative
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Build your personal Evidence Workspace

Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

evidence suggest

Evidence Suggest

  • Colchicine reduced cardiovascular death by 36% in participants without diabetes.
  • No significant difference in new-onset diabetes incidence between colchicine and placebo groups (1.5% vs. 2.2%).
  • In participants with T2DM, colchicine increased the risk of cardiovascular death (HR 1.52).
who this applies

Who this applies to

  • Adults with chronic coronary artery disease.
  • Patients with or without type 2 diabetes mellitus.
keep in mind

Keep in Mind

  • Results may not apply to younger populations or those without chronic coronary artery disease.
  • The study did not assess long-term effects beyond the trial duration.
  • Further research is needed to explore the effects of colchicine in diverse diabetes populations.
between the lines

Between the Lines

  • The effectiveness of colchicine in participants with T2DM was unclear.
  • The study's findings may not be generalizable to all populations with diabetes.
  • Sample size and demographic diversity may limit the robustness of the results.

Save this study

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Colchicine 0.5 mg once daily and Cardiovascular Outcomes, Colchicine 0.5 mg once daily and Coronary revascularization.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Explore more in the evidence archive

Jump to pre-filtered views in the evidence archive.

All studies on Colchicine 0.5 mg once daily and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Intervention: Colchicine 0.5 mg once dailyOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

1 results

All studies on Colchicine 0.5 mg once daily and Coronary revascularization

Intervention: Colchicine 0.5 mg once dailyOutcome: Coronary revascularization

1 results

All studies on Colchicine 0.5 mg once daily

Intervention: Colchicine 0.5 mg once daily

1 results

All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

1 results

All studies measuring Coronary revascularization

Outcome: Coronary revascularization

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Colchicine 0.5 mg once daily improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?

Emerging Evidence

Colchicine 0.5 mg once daily appears to improve Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Colchicine 0.5 mg once daily improve coronary revascularization?

Emerging Evidence

Colchicine 0.5 mg once daily appears to improve Coronary revascularization.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Coronary revascularization

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Colchicine 0.5 mg once daily improve incidence of myocardial infarction?

Emerging Evidence

Colchicine 0.5 mg once daily appears to improve Incidence of myocardial infarction.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Incidence of myocardial infarction

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Colchicine 0.5 mg once daily improve gestational diabetes mellitus incidence?

Emerging Evidence

Current evidence does not show a clear benefit of Colchicine 0.5 mg once daily for Gestational diabetes mellitus incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Gestational diabetes mellitus incidence

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Colchicine 0.5 mg once daily and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Colchicine 0.5 mg once daily and Coronary revascularizationAll studies on Colchicine 0.5 mg once daily and Incidence of myocardial infarctionAll studies on Colchicine 0.5 mg once daily and Ischemic stroke

Related research

Read related research summaries.

HbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsFinerenone reduces heart and kidney event risk in CKD and T2DIntensive glycemic control may lower cardiovascular events in some diabetes patientsSemaglutide may reduce cardiovascular events in non-diabetic patients.Semaglutide reduces cardiovascular events and body weight in T2D

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.